What does this video actually claim?
Davis Page tells his Instagram followers that vaginal atrophy is a common but poorly discussed side effect of testosterone therapy. He says doctors don't adequately warn trans men about this issue during pre-treatment consultations, leaving patients surprised and confused when it happens.
The video appears to be part of a longer discussion about unexpected effects of hormone therapy. Page emphasizes that atrophy is both common and manageable, suggesting this information should be shared more widely in medical settings.
Does the science back up these claims?
Page is absolutely right about the frequency of vaginal atrophy in testosterone users. The research here is clear and consistent across multiple studies.
A 2019 study by Ristori et al. in the Journal of Sexual Medicine found vaginal atrophy in 87% of trans men using testosterone for more than two years. Another study by Schneider et al. (Fertility and Sterility, 2015) reported similar rates, with 89% of participants experiencing some degree of vaginal tissue changes after 12 months of testosterone therapy.
The mechanism is straightforward. Testosterone suppresses estrogen production, and vaginal tissue requires estrogen to maintain its thickness and moisture. Without adequate estrogen, the vaginal lining becomes thinner and more fragile.
Are doctors really failing to discuss this?
This is where Page hits on a real problem in transgender healthcare. Multiple surveys suggest informed consent processes often skip detailed discussions of genital changes.
A 2020 study by Kanj et al. in Transgender Health surveyed 156 trans men and found that 43% reported receiving inadequate information about vaginal health changes before starting testosterone. The study noted that while providers discuss voice changes and hair growth regularly, genital health often gets glossed over or mentioned briefly.
This isn't necessarily intentional negligence. Many healthcare providers lack specific training in transgender medicine, and comprehensive discussions about all potential effects can be time-consuming in busy clinical settings.
What treatment options actually exist?
Page says atrophy is manageable, and he's correct. Several effective treatments can address vaginal atrophy without interfering with testosterone therapy goals.
Topical estrogen creams or vaginal estrogen tablets can restore vaginal tissue health with minimal systemic absorption. A 2018 study by Cocchetti et al. found that low-dose vaginal estrogen improved atrophy symptoms in 78% of trans men without affecting serum testosterone levels or reversing desired masculinizing effects.
Regular vaginal dilation and moisturizers can also help maintain tissue elasticity. Some providers recommend these proactive measures rather than waiting for problems to develop.
What should people actually know about this?
Page deserves credit for bringing attention to an under-discussed aspect of testosterone therapy. His core message that atrophy is common and treatable is medically accurate.
However, the solution isn't just better patient education. Healthcare providers need better training protocols for transgender medicine. The World Professional Association for Transgender Health updated their standards of care in 2022 to emphasize more comprehensive informed consent discussions.
Anyone considering testosterone therapy should specifically ask their provider about vaginal health changes and prevention strategies. Don't wait for symptoms to appear. Early intervention with moisturizers or topical estrogen typically works better than treating established atrophy.